Clinical Trials - February 25, 2014
The Data Inspection Board to look over research projects
The Swedish authority is initating an inspection of research projects of five pharmaceutical companies. The Data Inspection Board will among other things investigate how the companies inform participants about how their personal information will be handled and getting their approval to register this type of information. The five pharmaceutical companies are according to Läkemedelsvärlden and […]
Uncategorized - February 24, 2014
New research challenges classic model for gene regulation
For the first time ever, researchers at Uppsala University, have been able to study the process in living cells, showing that it may be more complex than previously thought. In all living organisms, genes are regulated by proteins called transcription factors. The established model states that a gene is switched off as long as a […]
Agreement - February 24, 2014
Dilafor in new license agreement
Dilafor AB, part of Karolinska Development’s portfolio of companies, has signed an agreement with Hong Kong-based biopharmaceutical firm. According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan. Pursuant to the terms of the agreement, Dilafor and Lee’s […]
Agreement - February 21, 2014
Mendor collaborates with Chinese distributor
The Finnish diabetes technology company has signed an exclusive distribution agreement for its blood glucose meter with Beijing Tagene Medical Co., Ltd. Under the agreement, Tagene will distribute the all-in-one blood glucose meter Mendor Discreet throughout China as of May this year for Mendor Discreet to be available to Chinese diabetes patients. “This is great news as we have worked hard […]
Agreement - February 21, 2014
Nuevolution enters license agreement with Merck
Nuevolution A/S has announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc. The agreement involves small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development. Under terms of the agreement, Merck will gain exclusive rights for the further development and […]
New Market - February 21, 2014
Novo Nordisk targets Mexico for anti-obesity drug
The Danish insulin maker plans to file for regulatory approval for the company’s new anti-obesity drug in Mexico, reports the Wall Street Journal. Novo Nordisk has reportedly targeted Mexico for an early launch of the treatment due to Mexico’s high percentage of overweight people, according to a statement from Mike Doustdar, senior vice president for international operations […]
